Several states across the country have reported cases of uncomfortable reactions to the Johnson & Johnson vaccine, and some areas have suspended vaccinations, but the federal Centers for Disease Control and Prevention (CDC) says “there is no reason to worry. On the other hand, the contamination of Baltimore’s Joulsen vaccine plant, which affects production, has begun to surface and will affect the vaccination schedule as vaccine distribution will be greatly reduced by nearly 90% next week.
Discomfort cases have been reported in Colorado, Iowa, Georgia and North Carolina, with the North Carolina Department of Health and Human Services and Wake County, as well as a vaccination center in Colorado and Georgia, announcing a suspension of the Jolson vaccine; according to Wake County officials, the “discomfort” cases are consistent with previous cases of New Crown vaccine. According to Wake County officials, the cases of “uncomfortable reactions” are consistent with the side effects of the previous New Crown vaccine, and are not unique.
The CDC reviewed the latest cases and concluded that “there is no reason for concern” and in fact, the incidence of adverse reactions to the Jovensen vaccine is low and not serious: a Wake County vaccination center received 2,300 doses of Jovensen vaccine and experienced 18 adverse reactions, of which only four required hospitalization and three were discharged; a K-State vaccination center received 1,700 doses of Jovensen vaccine and had only 13 adverse reactions. After 1,700 doses, only 13 people had uncomfortable reactions.
Production of frequent packs to be reduced next week
But even though the CDC recommends that the vaccine should be continued, the nation’s vaccine will be “out of stock” next week; distribution of the vaccine will drop from 572,700 doses to 67,600 doses in California, from 392,100 doses to 46,300 doses in Texas, from 313,200 doses to 37,000 doses in Florida, and from 313,200 doses to 37,000 doses in New York. to 37,000 doses, and New York State from more than 294,000 doses to less than 35,000 doses.
In Michigan, where the current wave of the epidemic is most severe, even though the governor has requested that priority be given to centralized vaccine distribution, the federal government is still insisting on the reality of distribution based on population, and the amount of distribution of Joulsen vaccine will drop from 148,000 doses to 17,500 doses, a drop of 88%.
Joulsen and partner pharmaceutical companies, Emergent BioSolutions in Baltimore factory production frequently out of the bag, production volume has been sharply reduced, next week around the Joulsen vaccine quantity is urgent. (Getty Images)
Nationwide, distribution of Jolson vaccine will drop 86 percent to 700,000 doses from 4.9 million this week.
Compared to Moderna and Pfizer vaccines, the Joulsen vaccine, which is produced in smaller doses but requires only one dose, is popular with many rural, more isolated or mobile populations across the country; many governors are concerned that a major shortage of Joulsen vaccine will affect vaccination schedules.
The reason for the major shortage of Joulsen vaccine is that its partner pharmaceutical company in Baltimore has mistakenly allowed Joulsen vaccine production lines to be contaminated with ingredients used in AstraZeneca’s AZ vaccine, resulting in an estimated 15 million doses of Joulsen vaccine being scrapped; the AZ vaccination has not yet been approved in the United States.
Joulsen anticipates that if it obtains federal approval to open the plant and resume production of the vaccine, 8 million doses of Joulsen vaccine could then be distributed nationwide each week.
Recent Comments